AstraZeneca PLC (AZN) - Net Assets

Latest as of June 2026: GBX50.63 Billion GBX ≈ $6.16 Million USD

Based on the latest financial reports, AstraZeneca PLC (AZN) has net assets worth GBX50.63 Billion GBX (≈ $6.16 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX116.43 Billion ≈ $14.17 Million USD) and total liabilities (GBX65.80 Billion ≈ $8.01 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check AZN strategic asset allocation to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric	Value
Current Net Assets	GBX50.63 Billion
% of Total Assets	43.49%
Annual Growth Rate	12.97%
5-Year Change	24.01%
10-Year Change	192.27%
Growth Volatility	213.92

AstraZeneca PLC - Net Assets Trend (1990–2025)

This chart illustrates how AstraZeneca PLC's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see AZN market cap.

Annual Net Assets for AstraZeneca PLC (1990–2025)

The table below shows the annual net assets of AstraZeneca PLC from 1990 to 2025. Also explore AZN shareholders equity momentum to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2025-12-31	GBX48.72 Billion ≈ $5.93 Million	+19.20%
2024-12-31	GBX40.87 Billion ≈ $4.97 Million	+4.35%
2023-12-31	GBX39.17 Billion ≈ $4.77 Million	+5.69%
2022-12-31	GBX37.06 Billion ≈ $4.51 Million	-5.67%
2021-12-31	GBX39.29 Billion ≈ $4.78 Million	+151.23%
2020-12-31	GBX15.64 Billion ≈ $1.90 Million	+7.14%
2019-12-31	GBX14.60 Billion ≈ $1.78 Million	+3.93%
2018-12-31	GBX14.04 Billion ≈ $1.71 Million	-15.61%
2017-12-31	GBX16.64 Billion ≈ $2.02 Million	-0.16%
2016-12-31	GBX16.67 Billion ≈ $2.03 Million	-9.61%
2015-12-31	GBX18.44 Billion ≈ $2.24 Million	-6.13%
2014-12-31	GBX19.65 Billion ≈ $2.39 Million	-15.51%
2013-12-31	GBX23.25 Billion ≈ $2.83 Million	-2.92%
2012-12-31	GBX23.95 Billion ≈ $2.91 Million	+2.04%
2011-12-31	GBX23.47 Billion ≈ $2.86 Million	+0.26%
2010-12-31	GBX23.41 Billion ≈ $2.85 Million	+12.43%
2009-12-31	GBX20.82 Billion ≈ $2.53 Million	+29.65%
2008-12-31	GBX16.06 Billion ≈ $1.95 Million	+7.68%
2007-12-31	GBX14.91 Billion ≈ $1.81 Million	-3.25%
2006-12-31	GBX15.42 Billion ≈ $1.88 Million	+12.60%
2005-12-31	GBX13.69 Billion ≈ $1.67 Million	-5.56%
2004-12-31	GBX14.50 Billion ≈ $1.76 Million	+9.35%
2003-12-31	GBX13.26 Billion ≈ $1.61 Million	+18.15%
2002-12-31	GBX11.22 Billion ≈ $1.37 Million	+16.53%
2001-12-31	GBX9.63 Billion ≈ $1.17 Million	+0.84%
2000-12-31	GBX9.55 Billion ≈ $1.16 Million	-7.71%
1999-12-31	GBX10.35 Billion ≈ $1.26 Million	-5.79%
1998-12-31	GBX10.98 Billion ≈ $1.34 Million	+203.07%
1997-12-31	GBX3.62 Billion ≈ $440.89K	-1.03%
1996-12-31	GBX3.66 Billion ≈ $445.48K	+20.58%
1995-12-31	GBX3.04 Billion ≈ $369.44K	+11.42%
1994-12-31	GBX2.73 Billion ≈ $331.56K	+17.26%
1993-12-31	GBX2.32 Billion ≈ $282.74K	+1268.01%
1992-12-31	GBX169.87 Million ≈ $20.67K	-81.47%
1991-12-31	GBX916.88 Million ≈ $111.56K	+34.27%
1990-12-31	GBX682.84 Million ≈ $83.08K	--

Equity Component Analysis

This analysis shows how different components contribute to AstraZeneca PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 1821.7% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	GBX10.97 Billion	22.55%
Common Stock	GBX388.00 Million	0.80%
Other Components	GBX37.31 Billion	76.66%
Total Equity	GBX48.67 Billion	100.00%

AstraZeneca PLC Competitors by Market Cap

The table below lists competitors of AstraZeneca PLC ranked by their market capitalization.

Company	Market Cap
NBCC (India) Limited NSE:NBCC	$2.39 Billion
Sichuan Development Lomon Co Ltd SHE:002312	$2.39 Billion
Coface SA PA:COFA	$2.39 Billion
SCHOTT Pharma AG & Co. KGaA XETRA:1SXP	$2.39 Billion
Huaming Power Equipment Co Ltd SHE:002270	$2.39 Billion
Guangdong Feinan Resources Recycling Co Ltd SHE:301500	$2.39 Billion
DO & CO Aktiengesellschaft VI:DOC	$2.39 Billion
NBT Bancorp Inc NASDAQ:NBTB	$2.39 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in AstraZeneca PLC's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 40,786,000,000 to 48,667,000,000, a change of 7,881,000,000 (19.3%).
Net income of 10,225,000,000 contributed positively to equity growth.
Dividend payments of 4,971,000,000 reduced retained earnings.
Other factors increased equity by 3,108,000,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	GBX10.22 Billion	+21.01%
Dividends Paid	GBX4.97 Billion	-10.21%
Other Changes	GBX3.11 Billion	+6.39%
Total Change	GBX-	19.32%

Book Value vs Market Value Analysis

This analysis compares AstraZeneca PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 406.72x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 15903.99x to 406.72x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
1990-12-31	GBX0.80	GBX12672.00	x
1991-12-31	GBX1.09	GBX12672.00	x
1992-12-31	GBX0.12	GBX12672.00	x
1993-12-31	GBX2.61	GBX12672.00	x
1994-12-31	GBX2.78	GBX12672.00	x
1995-12-31	GBX3.04	GBX12672.00	x
1996-12-31	GBX3.68	GBX12672.00	x
1997-12-31	GBX3.75	GBX12672.00	x
1998-12-31	GBX11.71	GBX12672.00	x
1999-12-31	GBX5.80	GBX12672.00	x
2000-12-31	GBX5.39	GBX12672.00	x
2001-12-31	GBX5.45	GBX12672.00	x
2002-12-31	GBX6.44	GBX12672.00	x
2003-12-31	GBX7.71	GBX12672.00	x
2004-12-31	GBX8.61	GBX12672.00	x
2005-12-31	GBX8.40	GBX12672.00	x
2006-12-31	GBX9.75	GBX12672.00	x
2007-12-31	GBX9.87	GBX12672.00	x
2008-12-31	GBX10.95	GBX12672.00	x
2009-12-31	GBX14.25	GBX12672.00	x
2010-12-31	GBX16.05	GBX12672.00	x
2011-12-31	GBX17.01	GBX12672.00	x
2012-12-31	GBX18.78	GBX12672.00	x
2013-12-31	GBX18.52	GBX12672.00	x
2014-12-31	GBX15.53	GBX12672.00	x
2015-12-31	GBX14.62	GBX12672.00	x
2016-12-31	GBX11.73	GBX12672.00	x
2017-12-31	GBX11.81	GBX12672.00	x
2018-12-31	GBX9.84	GBX12672.00	x
2019-12-31	GBX10.09	GBX12672.00	x
2020-12-31	GBX11.90	GBX12672.00	x
2021-12-31	GBX27.52	GBX12672.00	x
2022-12-31	GBX23.74	GBX12672.00	x
2023-12-31	GBX25.06	GBX12672.00	x
2024-12-31	GBX26.09	GBX12672.00	x
2025-12-31	GBX31.16	GBX12672.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently AstraZeneca PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 21.01%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 17.41%
• Asset Turnover: 0.51x
• Equity Multiplier: 2.34x
Recent ROE (21.01%) is below the historical average (30.12%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
1990	75.00%	5.83%	1.20x	10.69x	GBX371.13 Million
1991	82.54%	8.78%	1.16x	8.13x	GBX567.34 Million
1992	145.45%	2.01%	0.98x	74.18x	GBX112.99 Million
1993	28.75%	9.71%	0.88x	3.35x	GBX415.80 Million
1994	26.29%	9.89%	0.96x	2.78x	GBX429.15 Million
1995	18.05%	6.86%	0.96x	2.74x	GBX231.63 Million
1996	31.61%	11.99%	1.07x	2.46x	GBX752.82 Million
1997	33.80%	14.05%	1.04x	2.32x	GBX849.70 Million
1998	10.84%	12.96%	0.49x	1.69x	GBX92.26 Million
1999	11.09%	6.20%	0.93x	1.92x	GBX112.74 Million
2000	26.67%	14.02%	0.98x	1.94x	GBX1.59 Billion
2001	43.36%	17.63%	1.27x	1.93x	GBX3.20 Billion
2002	25.38%	15.90%	0.83x	1.93x	GBX1.72 Billion
2003	23.04%	16.11%	0.80x	1.79x	GBX1.72 Billion
2004	26.69%	17.10%	0.88x	1.78x	GBX2.40 Billion
2005	32.80%	19.65%	0.91x	1.83x	GBX3.10 Billion
2006	42.00%	22.83%	0.94x	1.96x	GBX4.90 Billion
2007	37.59%	18.93%	0.61x	3.25x	GBX4.08 Billion
2008	37.20%	19.31%	0.65x	2.95x	GBX4.33 Billion
2009	37.51%	22.93%	0.62x	2.66x	GBX5.68 Billion
2010	34.75%	24.21%	0.59x	2.42x	GBX5.74 Billion
2011	41.51%	29.72%	0.61x	2.27x	GBX7.33 Billion
2012	26.64%	22.31%	0.53x	2.26x	GBX3.95 Billion
2013	11.45%	9.94%	0.48x	2.41x	GBX335.65 Million
2014	6.13%	4.64%	0.44x	2.99x	GBX-760.39 Million
2015	14.79%	11.43%	0.40x	3.25x	GBX886.49 Million
2016	21.43%	15.21%	0.33x	4.21x	GBX1.70 Billion
2017	20.94%	13.36%	0.37x	4.23x	GBX1.64 Billion
2018	16.42%	9.76%	0.35x	4.86x	GBX800.42 Million
2019	10.22%	5.47%	0.40x	4.68x	GBX28.61 Million
2020	21.70%	11.58%	0.44x	4.27x	GBX1.83 Billion
2021	0.28%	0.30%	0.35x	2.68x	GBX-3.82 Billion
2022	8.86%	7.41%	0.46x	2.61x	GBX-422.93 Million
2023	15.47%	13.00%	0.46x	2.58x	GBX2.14 Billion
2024	16.89%	13.01%	0.51x	2.55x	GBX2.81 Billion
2025	21.01%	17.41%	0.51x	2.34x	GBX5.36 Billion

Industry Comparison

This section compares AstraZeneca PLC's net assets metrics with peer companies in the Drug Manufacturers - General industry.

Industry Context

Industry: Drug Manufacturers - General
Average net assets among peers: $2,805,000,000
Average return on equity (ROE) among peers: 28.77%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
AstraZeneca PLC (AZN)	GBX50.63 Billion	75.00%	1.30x	$2.39 Billion
GlaxoSmithKline PLC (GSK)	$2.81 Billion	28.77%	0.60x	$931.50 Million

About AstraZeneca PLC

LSE:AZN UK Drug Manufacturers - General

Market Cap

$2.39 Billion

GBX19.65 Trillion GBX

Market Cap Rank

#5622 Global

#14 in UK

Share Price

GBX12672.00

Change (1 day)

+0.89%

52-Week Range

GBX10956.00 - GBX15542.00

All Time High

GBX15542.00